Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation.

Area of Science:

• Immunology
• Oncology
• Radiotherapy

Background:

• Radiotherapy (RT) can stimulate anti-tumor immunity but adaptive resistance limits its effectiveness.
• RT-induced inflammation and T-cell infiltration are counteracted by PD-L1 expression, creating an immunosuppressive tumor microenvironment.
• Sequential administration of RT and checkpoint blockade immunotherapy (CBI) may overcome PD-L1-mediated suppression.

Purpose of the Study:

• To determine the optimal timing for combining RT with anti-PD-L1 therapy to enhance anti-tumor immune responses.
• To investigate how the timing of CBI affects T-cell infiltration and PD-L1 expression in the tumor microenvironment after RT.

Main Methods:

• BALB/c mice with CT26 or 4T1 tumors received 10 Gy RT followed by anti-PD-L1 (0.2 mg) at varying intervals (0-7 days).
• Tumor response, anti-PD-L1 delivery, T-cell infiltration (TILs), and PD-L1 expression were quantified.
• Tumor growth was monitored using calipers.

Main Results:

• RT alone caused transient tumor growth delay with peak CTLs at 3 days and PD-L1 at 5 days, followed by CTL decline.
• Anti-PD-L1 only enhanced RT efficacy when administered 5 days post-RT, preventing CTL depletion and leading to tumor elimination.
• Irradiation enhanced anti-PD-L1 tumor penetration and binding.

Conclusions:

• A 5-day interval between RT and anti-PD-L1 administration is optimal for overcoming adaptive resistance.
• This strategy leverages RT-induced tumor permeability to improve CBI delivery and block PD-L1 signaling during its peak.
• Combining RT with precisely timed CBI offers a promising approach to potentiate anti-tumor immunity and improve radiotherapy outcomes.